556 related articles for article (PubMed ID: 22717740)
21. Use of SLAM and PVRL4 and identification of pro-HB-EGF as cell entry receptors for wild type phocine distemper virus.
Melia MM; Earle JP; Abdullah H; Reaney K; Tangy F; Cosby SL
PLoS One; 2014; 9(8):e106281. PubMed ID: 25171206
[TBL] [Abstract][Full Text] [Related]
22. Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.
Fujiyuki T; Amagai Y; Shoji K; Kuraishi T; Sugai A; Awano M; Sato H; Hattori S; Yoneda M; Kai C
Mol Ther Oncolytics; 2020 Dec; 19():127-135. PubMed ID: 33145396
[TBL] [Abstract][Full Text] [Related]
23. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
24. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
25. Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model.
Vongpunsawad S; Oezgun N; Braun W; Cattaneo R
J Virol; 2004 Jan; 78(1):302-13. PubMed ID: 14671112
[TBL] [Abstract][Full Text] [Related]
26. Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration.
Condack C; Grivel JC; Devaux P; Margolis L; Cattaneo R
J Infect Dis; 2007 Aug; 196(4):541-9. PubMed ID: 17624839
[TBL] [Abstract][Full Text] [Related]
27. Genetic changes that affect the virulence of measles virus in a rhesus macaque model.
Bankamp B; Hodge G; McChesney MB; Bellini WJ; Rota PA
Virology; 2008 Mar; 373(1):39-50. PubMed ID: 18155263
[TBL] [Abstract][Full Text] [Related]
28. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
30. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
31. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines.
Terao-Muto Y; Yoneda M; Seki T; Watanabe A; Tsukiyama-Kohara K; Fujita K; Kai C
Antiviral Res; 2008 Dec; 80(3):370-6. PubMed ID: 18812191
[TBL] [Abstract][Full Text] [Related]
32. Measles Virus Enters Breast and Colon Cancer Cell Lines through a PVRL4-Mediated Macropinocytosis Pathway.
Delpeut S; Sisson G; Black KM; Richardson CD
J Virol; 2017 May; 91(10):. PubMed ID: 28250131
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
34. SLAM (CDw150) is a cellular receptor for measles virus.
Tatsuo H; Ono N; Tanaka K; Yanagi Y
Nature; 2000 Aug; 406(6798):893-7. PubMed ID: 10972291
[TBL] [Abstract][Full Text] [Related]
35. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein.
Hashimoto K; Ono N; Tatsuo H; Minagawa H; Takeda M; Takeuchi K; Yanagi Y
J Virol; 2002 Jul; 76(13):6743-9. PubMed ID: 12050387
[TBL] [Abstract][Full Text] [Related]
36. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.
Anderson BD; Nakamura T; Russell SJ; Peng KW
Cancer Res; 2004 Jul; 64(14):4919-26. PubMed ID: 15256464
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors.
Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM
Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138
[TBL] [Abstract][Full Text] [Related]
39. Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule.
Takeda S; Kanbayashi D; Kurata T; Yoshiyama H; Komano J
Cancer Sci; 2014 Feb; 105(2):211-8. PubMed ID: 24238277
[TBL] [Abstract][Full Text] [Related]
40. A human lung carcinoma cell line supports efficient measles virus growth and syncytium formation via a SLAM- and CD46-independent mechanism.
Takeda M; Tahara M; Hashiguchi T; Sato TA; Jinnouchi F; Ueki S; Ohno S; Yanagi Y
J Virol; 2007 Nov; 81(21):12091-6. PubMed ID: 17715217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
